MedTrace Logo

Cotrifazid Safety and Efficacy Against Malaria

NCT00322907 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 330

Last updated 2006-05-08

No results posted yet for this study

Summary

The purpose of this study was to assess the safety and efficacy of Cotrifazid to treat uncomplicated resistant malaria and to compare the outcome with mefloquine or quinine+sulfadoxine/pyrimethamine (SP)

Conditions

  • Clinical Malaria

Interventions

DRUG

Cotrifazid vs mefloquine or quinine+SP

Sponsors & Collaborators

  • Papua New Guinea Institute of Medical Research

    collaborator OTHER_GOV

  • Swiss Tropical & Public Health Institute

    collaborator OTHER

  • Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland

    lead OTHER

Principal Investigators

  • Blaise Genton, MD, PhD · Swiss Tropical & Public Health Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
6 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-04-30
Completion
2003-01-31

Countries

  • Papua New Guinea

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00322907 on ClinicalTrials.gov